WOBURN, Mass.–(BUSINESS WIRE)–#AlzheimersDisease–Aphios Corporation today announced that it has been granted Chinese Patent No. 201811111996.8 by China National Intellectual Property Administration on October 26, 2021. The patent entitled, �Bryoid Compositions, Methods of Making and Use Thereof,� covers novel composition of matter of the novel Bryoid, Bryostatin-23 and use for the treatment of Alzheimer�s disease and other neurodegenerative diseases, virus latency diseases such as HIV and Herpes, cancers and glaucoma.
According to Dr. Trevor P. Castor, President and CEO, Aphios Corporation: �This novel Bryoid, Bryostatin-23, is a highly potent nanomolar activator of ?-secretase activity in neuroblastoma cell models, being more effective than the canonical Bryostatin-1 at increasing activity of all protein kinase C (PKC) isoforms, particularly the novel PKC isoforms, delta and epsilon. It thus has a higher therapeutic efficacy than Bryostatin-1.�
About Aphios Corporation: Aphios Corporation (www.aphios.com) is a green biotechnology company developing enabling technology platforms for improving drug discovery, manufacturing, delivery and safety, and enhanced natural therapeutics for health maintenance and disease prevention, and treatment of Alzheimer�s disease.
Contacts
Trevor P. Castor, Ph.D., CEO
(001) 781-858-7520
[email protected]
